Anthem Biosciences IPO
Anthem Biosciences IPO
Overview
Anthem Biosciences IPO is a bookbuilding of ₹3,395.00 crores. The issue is entirely an offer for sale of 5.96 crore shares. Anthem Biosciences IPO opens for subscription on July 14, 2025 and closes on July 16, 2025. The allotment for the Anthem Biosciences IPO is expected to be finalized on Thursday, July 17, 2025. Anthem Biosciences IPO will be list on BSE, NSE with a tentative listing date fixed as Monday, July 21, 2025. Anthem Biosciences IPO price band is set at ₹540 to ₹570 per share. The lot size for an application is 26. The minimum amount of investment required by an retail is ₹14,040 (26 shares). The lot size investment for sNII is 14 lots (364 shares), amounting to ₹2,07,480, and for bNII, it is 68 lots (1,768 shares), amounting to ₹10,07,760. Jm Financial Limited is the book-running lead manager of the Anthem Biosciences IPO, while Kfin Technologies Limited is the registrar for the issue. Refer to Anthem Biosciences IPO RHP for detailed information.
Total Shares
5,95,61,404
Issue Size
₹3,395.00 Cr
Price Band
₹540 – ₹570
Lot Size
26 shares
Min. Investment
₹14,820
Max. Investment
₹1,92,660
Open Date
14 Jul, 2025
Close Date
16 Jul, 2025
Allotment
17 Jul, 2025
Listing
21 Jul, 2025
Max. Investment
₹1,92,660
Announced
14 Jul, 2025
Opening Date
14 Jul, 2025
Closing Date
16 Jul, 2025
Basis of Allotment
17 Jul, 2025
Initiation of Refunds
18 Jul, 2025
Credit of Shares
18 Jul, 2025
Listing Date
21 Jul, 2025
Live GMP
Est. Listing: ₹662
Apply via UPI in 5 minutes
Choose your broker • Zero commission on IPO
About Anthem Biosciences IPO
Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes.
The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale.
The company manufactures specialized fermentation-based APIs, including pro
Anthem Biosciences IPO Share Price
Issue Breakdown
Shareholding
Dilution: 0.0% increase in shares
Anthem Biosciences IPO Promoters Holding
Anthem Biosciences IPO Financial Health
Anthem Biosciences Ltd.'s revenue increased by 30% and profit after tax (PAT) rose by 23% between the financial year ending with March 31, 2025 and March 31, 2024.
Anthem Biosciences IPO Lot Size
Investors can bid for a minimum of 26 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 26 | ₹14,820 |
| Retail (Max) | 13 | 338 | ₹1,92,660 |
| S-HNI (Min) | 14 | 364 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1742 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1768 | ₹10,07,760 |
(All values in CR)
Anthem Biosciences IPO Valuations
The market capitalization of Anthem Biosciences IPO is ₹31867.39 Cr. KPI as of Mon, Mar 31, 2025.
| Metric | Value |
|---|---|
| ROE | 20.82 |
| ROCE | 26.88 |
| Debt/Equity | 0.05 |
| RoNW | 20.82 |
| PAT Margin | 23.38 |
| EBITDA Margin | 36.81 |
| Price to Book Value | 13.23 |
(All values in CR)
Anthem Biosciences IPO Strength & Risk
Anthem Biosciences IPO Strength:
- One-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India's fastest growing CRDMO.
- Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
- Specialized business model for small pharmaceutical and biotech companies, from discovery to manufacturing.
- Long-standing relationships with a large, diversified and loyal customer base.
- Professional and experienced leadership team supported by a qualified scientific talent pool.
Anthem Biosciences IPO Risk:
100% Offer-for-Sale (OFS):
No fresh issue; all ₹3,395 crore goes to existing shareholders, not to the company — limiting future investment or growth.High Revenue Concentration:
Top 5 customers contribute ~70.9% of revenue. Loss of any key client could materially affect financials.Dependence on U.S. Sales Channel:
Relies on DavosPharma (affiliate of a selling shareholder) for U.S. business. Any disruption in this partnership poses significant risk.Overreliance on CRDMO Segment:
81.6% of revenue comes from contract research and manufacturing. A slowdown in this space can directly impact topline.Regulatory and Clinical Risks:
Business depends on clients' success in clinical trials, which carry high failure rates, especially in late-stage phases.No Direct Funding for Expansion:
With no fresh issue, ongoing capex and capacity expansion (like Unit III and IV) must be internally financed or debt-funded.IPO Market Volatility:
Weak investor sentiment, global macro uncertainty, and past delays raise concerns over post-listing performance.
Anthem Biosciences IPO GMP
Anthem Biosciences IPO last GMP is ₹92, last updated Jul 12th 2025 05:37 PM. With the price band of 570.00, Anthem Biosciences IPO's estimated listing price is ₹662 (cap price + today's GMP).The expected percentage gain/loss per share is 16.14%. >> Anthem Biosciences IPO Retail Subject to Sauda: ₹1800 >> Anthem Biosciences IPO Small HNI Subject to Sauda: ₹25200 The lowest GMP is ₹0.00, while the highest GMP is ₹107.00.
Last updated 12 Jul, 2025 · Source: aggregated grey-market dealers
| Date | IPO Price | GMP | Sub2 Sauda | Est. Listing | Est. Profit | Updated |
|---|---|---|---|---|---|---|
| 12 Jul, 2025 | 570 | ₹92 | 1800/25200 | ₹662 (16.14%) | 2392 | 12 Jul, 2025 |
| 11 Jul, 2025 | 570 | ₹92▼ | 1800/25200 | ₹662 (16.14%) | 2392 | 11 Jul, 2025 |
| 10 Jul, 2025 | 570 | ₹107▲ | 2100/29400 | ₹677 (18.77%) | 2782 | 10 Jul, 2025 |
| 09 Jul, 2025 | 570 | ₹103▲ | 2000/28000 | ₹673 (18.07%) | 2678 | 09 Jul, 2025 |
| 08 Jul, 2025 | 0 | ₹66▲ | - | ₹66 (0.00%) | - | 08 Jul, 2025 |
| 07 Jul, 2025 | 0 | ₹0 | - | ₹ (0.00%) | - | 07 Jul, 2025 |
| 06 Jul, 2025 | 0 | ₹0 | - | ₹ (0.00%) | - | 06 Jul, 2025 |
| 05 Jul, 2025 | 0 | ₹0 | - | ₹ (0.00%) | - | 05 Jul, 2025 |
| 04 Jul, 2025 | 0 | ₹0 | - | ₹ (0.00%) | - | 04 Jul, 2025 |
| 03 Jul, 2025 | 0 | ₹0 | - | ₹ (0.00%) | - | 03 Jul, 2025 |
| 30 Jun, 2025 | 0 | ₹0 | - | ₹ (%) | - | 30 Jun, 2025 |
| 02 Jul, 2025 | 0 | ₹0 | - | ₹ (0.00%) | - | 02 Jul, 2025 |
| 01 Jul, 2025 | 0 | ₹0 | - | ₹ (0.00%) | - | 01 Jul, 2025 |
Disclaimer: GMP is an unofficial signal from grey-market dealers and is not regulated by SEBI. Use it alongside subscription data and other research for informed decision-making.
How to Apply for Anthem Biosciences IPO
Login to Your Trading App
Open Zerodha, Upstox, Groww, Angel One, or any brokerage app.
Go to IPO Section
Find Anthem Biosciences IPO under the IPO section. Select it and enter your bid details — choose lot size and price (cut-off price recommended).
Enter UPI ID and Submit
Provide your UPI ID linked to your bank account and submit the application.
Approve Mandate on UPI App
Open your UPI app (Google Pay, PhonePe, Paytm, BHIM) and approve the IPO payment request.
Application Confirmed
Your funds will be blocked in your account until the IPO allotment process is completed.